PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-5.62
Negative P/E while Healthcare median is -3.21. Seth Klarman would scrutinize path to profitability versus peers.
No Data
No Data available this quarter, please select a different quarter.
2.34
P/B 50-90% of Healthcare median of 3.61. Mohnish Pabrai would examine if this discount presents opportunity.
-22.04
Negative FCF while Healthcare median P/FCF is -11.02. Seth Klarman would investigate cash flow improvement potential.
-22.90
Negative operating cash flow while Healthcare median P/OCF is -7.26. Seth Klarman would investigate operational improvement potential.
2.34
Fair value ratio 50-90% of Healthcare median of 3.62. Mohnish Pabrai would examine if this gap presents opportunity.
-4.45%
Negative earnings while Healthcare median yield is -0.75%. Seth Klarman would investigate path to profitability.
-4.54%
Negative FCF while Healthcare median yield is -0.34%. Seth Klarman would investigate cash flow improvement potential.